Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
2(33%)
Results Posted
0%(0 trials)

Phase Distribution

Ph early_phase_1
1
17%
Ph not_applicable
1
17%
Ph phase_2
3
50%

Phase Distribution

1

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Early Phase 1First-in-human
1(20.0%)
Phase 2Efficacy & side effects
3(60.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(3)
Completed(2)
Other(1)

Detailed Status

Recruiting2
Completed2
Not yet recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (20.0%)
Phase 23 (60.0%)
N/A1 (20.0%)

Trials by Status

not_yet_recruiting117%
recruiting233%
completed233%
unknown117%

Recent Activity

2 active trials
Showing 5 of 6
recruitingphase_2

Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)

NCT04591002
completedphase_2

Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients

NCT04184921
recruitingphase_2

A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC

NCT07058519
not_yet_recruitingearly_phase_1

CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC

NCT06557096
completed

First Line Osimertinib in the Real World: an Inter-regional Prospective Study

NCT04965701
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04591002Phase 2

Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)

Recruiting
NCT04184921Phase 2

Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients

Completed
NCT07058519Phase 2

A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC

Recruiting
NCT06557096Early Phase 1

CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC

Not Yet Recruiting
NCT04965701

First Line Osimertinib in the Real World: an Inter-regional Prospective Study

Completed
NCT05583409Not Applicable

SBRT Combined With Osimertinib Compared With Osimertinib for Stage IV NSCLC

Unknown

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6